Bulletin
Investor Alert

New York Markets Close in:

Biogen Inc.

NAS: BIIB

GO
/marketstate/country/us

Market open

 --Real time quotes

Jul 6, 2020, 2:34 p.m.

/zigman2/quotes/201531540/composite

$

268.00

Change

+2.88 +1.09%

Volume

Volume 430,000

Real time quotes

/zigman2/quotes/201531540/composite

Previous close

$ 265.12

$ 268.00

Change

+2.88 +1.09%

Day low

Day high

$267.13

$270.71

Open

52 week low

52 week high

$215.78

$374.99

Open

Company Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment o...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Valuation

P/E Current

8.44

P/E Ratio (with extraordinary items)

7.81

P/E Ratio (without extraordinary items)

9.44

Price to Sales Ratio

4.37

Price to Book Ratio

3.87

Price to Cash Flow Ratio

7.86

Enterprise Value to EBITDA

9.07

Enterprise Value to Sales

4.53

Total Debt to Enterprise Value

0.11

Efficiency

Revenue/Employee

1,718,108.00

Income Per Employee

795,743.00

Receivables Turnover

5.13

Total Asset Turnover

0.48

Liquidity

Current Ratio

1.72

Quick Ratio

1.56

Cash Ratio

0.92

Profitability

Gross Margin

80.97

Operating Margin

45.85

Pretax Margin

56.05

Net Margin

46.32

Return on Assets

22.42

Return on Equity

44.64

Return on Total Capital

30.09

Return on Invested Capital

31.67

Capital Structure

Total Debt to Total Equity

48.27

Total Debt to Total Capital

32.56

Total Debt to Total Assets

23.65

Long-Term Debt to Equity

36.51

Long-Term Debt to Total Capital

24.62

Officers and Executives

Name Age Officer Since Title
Mr. Michel Vounatsos 57 2016 Chief Commercial Officer & Executive VP
Mr. Jeffrey D. Capello 64 2017 Chief Financial Officer & Executive Vice President
Dr. Alfred W. Sandrock 61 1998 Chief Medical Officer
Mr. Mark Hernon - 2017 Chief Information Officer & Senior Vice President
Dr. Alphonse Galdes - 1995 EVP-Pharmaceutical Operations & Technology

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/03/2020 Stelios B. Papadopoulos
Director
1,470   Award at $0 per share. 0
06/03/2020 Caroline D. Dorsa
Director
890   Award at $0 per share. 0
06/03/2020 Robert W. Pangia
Director
890   Award at $0 per share. 0
06/03/2020 Stephen A. Sherwin
Director
890   Award at $0 per share. 0
06/03/2020 Eric K. Rowinsky
Director
890   Award at $0 per share. 0
06/03/2020 Nancy L. Leaming
Director
890   Award at $0 per share. 0
06/03/2020 Alexander John Denner
Director
890   Award at $0 per share. 0
06/03/2020 Richard Charles Mulligan
Director
890   Award at $0 per share. 0
06/03/2020 Brian S. Posner
Director
890   Award at $0 per share. 0
06/03/2020 Jesus B. Mantas
Director
890   Award at $0 per share. 0
06/03/2020 William A. Hawkins
Director
890   Award at $0 per share. 0
03/11/2020 Stephen A. Sherwin
Director
270   Disposition at $295.29 per share. 79,728
03/11/2020 Stephen A. Sherwin
Director
2,164   Disposition at $295.22 per share. 638,856
03/11/2020 Stephen A. Sherwin
Director
1,355   Derivative/Non-derivative trans. at $58.46 per share. 79,213
03/11/2020 Stephen A. Sherwin
Director
10,923   Derivative/Non-derivative trans. at $58.46 per share. 638,558
02/15/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
689   Derivative/Non-derivative trans. at $333 per share. 229,437
02/15/2020 Michel Vounatsos
Chief Executive Officer; Director
2,150   Derivative/Non-derivative trans. at $333 per share. 715,950
02/15/2020 Alfred W. Sandrock
EVP, Research & Development
538   Derivative/Non-derivative trans. at $333 per share. 179,154
02/15/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
130   Derivative/Non-derivative trans. at $333 per share. 43,290
02/15/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
1,553   Derivative/Non-derivative trans. at $0 per share. 0
02/15/2020 Michel Vounatsos
Chief Executive Officer; Director
4,847   Derivative/Non-derivative trans. at $0 per share. 0
02/15/2020 Alfred W. Sandrock
EVP, Research & Development
1,213   Derivative/Non-derivative trans. at $0 per share. 0
02/15/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
441   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
681   Derivative/Non-derivative trans. at $331.76 per share. 225,928
02/12/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
798   Derivative/Non-derivative trans. at $331.76 per share. 264,744
02/12/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
756   Derivative/Non-derivative trans. at $331.76 per share. 250,810
02/12/2020 Michel Vounatsos
Chief Executive Officer; Director
2,555   Derivative/Non-derivative trans. at $331.76 per share. 847,646
02/12/2020 Michel Vounatsos
Chief Executive Officer; Director
2,340   Derivative/Non-derivative trans. at $331.76 per share. 776,318
02/12/2020 Alfred W. Sandrock
EVP, Research & Development
703   Derivative/Non-derivative trans. at $331.76 per share. 233,227
02/12/2020 Alfred W. Sandrock
EVP, Research & Development
538   Derivative/Non-derivative trans. at $331.76 per share. 178,486
02/12/2020 Alfred W. Sandrock
EVP, Research & Development
660   Derivative/Non-derivative trans. at $331.76 per share. 218,961
02/12/2020 Ginger Gregory
EVP, Human Resources
418   Derivative/Non-derivative trans. at $331.76 per share. 138,675
02/12/2020 Ginger Gregory
EVP, Human Resources
286   Derivative/Non-derivative trans. at $331.76 per share. 94,883
02/12/2020 Ginger Gregory
EVP, Human Resources
455   Derivative/Non-derivative trans. at $331.76 per share. 150,950
02/12/2020 Chirfi Guindo
EVP Glob. Prod Strat and Comm
504   Derivative/Non-derivative trans. at $331.76 per share. 167,207
02/12/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
106   Derivative/Non-derivative trans. at $331.76 per share. 35,166
02/12/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
92   Derivative/Non-derivative trans. at $331.76 per share. 30,521
02/12/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
153   Derivative/Non-derivative trans. at $331.76 per share. 50,759
02/12/2020 Jeffrey D. Capello
EVP & Chief Financial Officer
614   Derivative/Non-derivative trans. at $331.76 per share. 203,700
02/12/2020 Daniel Karp
EVP, Corporate Development
294   Derivative/Non-derivative trans. at $331.76 per share. 97,537
02/12/2020 Robin C. Kramer
VP, Chief Accounting Officer
46   Derivative/Non-derivative trans. at $331.76 per share. 15,260
02/12/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
1,535   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
2,697   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Susan H. Alexander
EVP Chief Legal Off & Corp Sec
1,735   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Michel Vounatsos
Chief Executive Officer; Director
5,760   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Michel Vounatsos
Chief Executive Officer; Director
6,234   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Alfred W. Sandrock
EVP, Research & Development
1,583   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Alfred W. Sandrock
EVP, Research & Development
1,422   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Alfred W. Sandrock
EVP, Research & Development
2,211   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Ginger Gregory
EVP, Human Resources
1,056   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Ginger Gregory
EVP, Human Resources
974   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Ginger Gregory
EVP, Human Resources
1,517   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Chirfi Guindo
EVP Glob. Prod Strat and Comm
1,680   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
358   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
312   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Alphonse Galdes
EVP Pharmaceutical Oper & Tech
484   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Jeffrey D. Capello
EVP & Chief Financial Officer
1,919   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Daniel Karp
EVP, Corporate Development
960   Derivative/Non-derivative trans. at $0 per share. 0
02/12/2020 Robin C. Kramer
VP, Chief Accounting Officer
132   Derivative/Non-derivative trans. at $0 per share. 0
01/02/2020 Jeffrey D. Capello
EVP & Chief Financial Officer
406   Derivative/Non-derivative trans. at $294.2 per share. 119,445
01/02/2020 Jeffrey D. Capello
EVP & Chief Financial Officer
1,302   Derivative/Non-derivative trans. at $0 per share. 0
12/03/2019 Robin C. Kramer
VP, Chief Accounting Officer
25   Derivative/Non-derivative trans. at $290.7 per share. 7,267
12/03/2019 Robin C. Kramer
VP, Chief Accounting Officer
84   Derivative/Non-derivative trans. at $0 per share. 0
12/02/2019 Brian S. Posner
Director
1,055   Disposition at $292.35 per share. 308,429
12/01/2019 Chirfi Guindo
EVP Glob. Prod Strat and Comm
160   Derivative/Non-derivative trans. at $299.81 per share. 47,969
12/01/2019 Chirfi Guindo
EVP Glob. Prod Strat and Comm
231   Derivative/Non-derivative trans. at $299.81 per share. 69,256
12/01/2019 Chirfi Guindo
EVP Glob. Prod Strat and Comm
543   Derivative/Non-derivative trans. at $0 per share. 0
11/04/2019 Stephen A. Sherwin
Director
200   Gift at $0 per share. 0
11/04/2019 Stephen A. Sherwin
Director
200   Gift at $0 per share. 0
11/04/2019 Stephen A. Sherwin
Director
325   Gift at $0 per share. 0
08/01/2019 Ginger Gregory
EVP, Human Resources
80   Derivative/Non-derivative trans. at $243.06 per share. 19,444
08/01/2019 Ginger Gregory
EVP, Human Resources
128   Derivative/Non-derivative trans. at $243.06 per share. 31,111
08/01/2019 Ginger Gregory
EVP, Human Resources
179   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/biib

MarketWatch News on BIIB

  1. Biogen Loses Another Bull Over Patent Worries

    12:00 p.m. June 22, 2020

    - Teresa Rivas

  2. How to Play Biotech’s Next Rise

    9:48 a.m. June 20, 2020

    - Ben Levisohn

  3. This Tiny ETF Is Fighting Racism and Beating the Market

    6:22 p.m. June 19, 2020

    - Evie Liu

  4. Biogen plans to appeal court decision invalidating a Tecfidera patent

    12:07 p.m. June 18, 2020

    - Tomi Kilgore

  5. Biogen Is Slumping After Judge Rules Against Its Biggest Drug

    11:02 a.m. June 18, 2020

    - Bill Alpert

  6. Royalty Pharma’s IPO Gets Enthusiastic Reception

    3:21 p.m. June 16, 2020

    - Bill Alpert

  7. Biogen stock price target cut to $297 from $360 at Bernstein

    6:16 a.m. June 10, 2020

    - Tomi Kilgore

  8. Biogen downgraded to market perform from outperform at Bernstein

    6:16 a.m. June 10, 2020

    - Tomi Kilgore

  9. S&P Slips as Nasdaq Hits New High, Nearing 10,000

    4:16 p.m. June 9, 2020

    - Nicholas Jasinski

  10. Risk to a Key Biogen Patent Prompts a Bernstein Downgrade

    12:30 p.m. June 9, 2020

    - Bill Alpert

  11. Dow Slumps Because Stocks Can’t Go Up Forever

    8:24 a.m. June 9, 2020

    - Carleton English

  12. Zoom Video, Slack, Broadcom, and Other Stocks to Watch This Week

    3:00 p.m. May 31, 2020

    - Nicholas Jasinski

  13. Streaming Services Have Rescued the Record Business

    9:05 p.m. May 29, 2020

    - Nicholas Jasinski

  14. Loading more headlines...
/news/nonmarketwatch/company/us/biib

Other News on BIIB

  1. Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years

    6:40 a.m. Today

    - InvestorPlace.com

  2. Coronavirus Is No Cure for Health-Care Stocks

    6:15 p.m. July 5, 2020

    - Caitlin McCabe

  3. 5 Health Care Stocks Boosting Earnings

    9:18 a.m. June 30, 2020

    - GuruFocus.com

  4. Biogen and Southwest Are on the Casualty List

    8:49 a.m. June 29, 2020

    - GuruFocus.com

  5. Short Sellers Run for Cover From Major Biotechs

    9:03 a.m. June 25, 2020

    - 247WallSt.com

  6. Own Biogen For Long-Term Safety And Growth

    8:36 p.m. June 22, 2020

    - Seeking Alpha

  7. Barclays bails on Biogen after court ruling

    8:25 a.m. June 22, 2020

    - Seeking Alpha

  8. US Indexes Report Gains for the June 19 Week

    4:43 p.m. June 19, 2020

    - GuruFocus.com

  9. William Blair Sticks to Its Hold Rating for Biogen (BIIB)

    10:06 a.m. June 19, 2020

    - SmarterAnalyst

  10. Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan

    9:34 a.m. June 19, 2020

    - Zacks.com

  11. Loading more headlines...

At a Glance

Biogen, Inc.

225 Binney Street

Cambridge, Massachusetts 02142

Phone

1 6176792000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$12.71B

Net Income

$5.89B

2019 Sales Growth

5.5%

Employees

7,400

/news/pressrelease/company/us/biib

Press Releases on BIIB

  1. US Stocks That Surged Higher This Week: $BIIB $EA $GS

    9:20 a.m. June 26, 2020

    - The Market Signal

  2. Loading more headlines...
Link to MarketWatch's Slice.